XML Persian Abstract Print


Firoozabadi Clinical Research Development Unit (FCRDU), Iran University of Medical Sciences (IUMS), Tehran, Iran. , Amin.abbasi1314@gmail.com
Abstract:   (2212 Views)
Chronic lymphocytic leukemia (CLL) is one of the most common hematologic neoplasms leading to immunosuppression. It is characterized by absolute lymphocytosis with clonality of mature B cells. Therefore, they are vulnerable to various infections especially COVID-19. Little is known about the COVID-19 infection when it unmasks CLL.
We reported a 90-year-old man who presented with signs and symptoms of anorexia, weakness, and loss of consciousness, and lymphocytosis which in further workup COVID-19 confirmed with real-time PCR. Due to lymphocytosis, peripheral blood smear (PBS) and flow cytometry were performed and CLL was diagnosed. His lymphocyte count increased to 1.5-fold during hospitalization. The patient recovered after 11 days as the symptoms were alleviated.
Lymphocytosis is an unexpected finding in patients diagnosed with COVID-19 infection, and an increase in lymphocytes may indicate other conditions. In these cases, secondary causes of lymphocytosis, such as malignancy or other infections, should be considered
Full-Text [PDF 720 kb]   (1040 Downloads)    
Type of Study: case report | Subject: Special

References
1. Zhou MY, Xie XL, Peng YG, Wu MJ, Deng XZ, Wu Y, et al. From SARS to COVID-19: What we have learned about children infected with COVID-19. Int J Infect Dis 2020;96:710-4. [DOI:10.1016/j.ijid.2020.04.090] [PMID] [PMCID]
2. Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia 2020;34(9):2354-63. [DOI:10.1038/s41375-020-0959-x] [PMID] [PMCID]
3. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv2019;3(9):1553-62. [DOI:10.1182/bloodadvances.2018030007] [PMID] [PMCID]
4. Jacque N, Leblond V. La leucémie lymphoïde chronique: mise au point [Chronic lymphocytic leukemia]. Presse Med 2019;48(7-8 Pt 1):807-15. [DOI:10.1016/j.lpm.2019.07.019] [PMID]
5. Charra B, Ellouadghiri A, Magramane A, Kebbou T, Damaan K, Maghfour A, et al. COVID-19 and fortuitous discovery of chronic lymphocytic leukemia: biological findings and therapeutic challenges. Pan Afr Med J 2020;36:286. [DOI:10.11604/pamj.2020.36.286.24361] [PMID] [PMCID]
6. Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 1986;63(2):377-87. [DOI:10.1111/j.1365-2141.1986.tb05563.x] [PMID]
7. Montserrat E. When CLL meets COVID-19. Blood 2020;136(10):1115-6. [DOI:10.1182/blood.2020008092] [PMID] [PMCID]
8. Safarpour D, Srinivasan K, Farooqui M, Roth C, Ghouse M. A Case of COVID-19-Induced Lymphocytosis in a Patient with Treatment-Naive CLL: Should It Be treated? Clin Lymphoma Myeloma Leuk 2020; S2152-650(20):30516-4. [Pub Med]
9. Wang K, Zuo P, Liu Y, Zhang M, Zhao X, Xie S, et al. Clinical and Laboratory Predictors of In-hospital Mortality in Patients With Coronavirus Disease-2019: A Cohort Study in Wuhan, China. Clin Infect Dis 2020; 71(16):2079-88. [DOI:10.1093/cid/ciaa538] [PMID] [PMCID]
10. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. Ebio Medicine 2020;55:102763. https://doi.org/10.2139/ssrn.3539682 https://doi.org/10.1101/2020.02.16.20023671 [DOI:10.1016/j.ebiom.2020.102763]
11. Ali E, Badawi M, Abdelmahmuod E, Kohla S, Yassin MA. Chronic Lymphocytic Leukemia Concomitant with COVID 19: A Case Report. Am J Case Rep 2020; 21:e926062. [DOI:10.12659/AJCR.926062] [PMID] [PMCID]
12. Paneesha S, Pratt G, Parry H, Moss P. Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia. Leuk Res 2020;93:106366. [DOI:10.1016/j.leukres.2020.106366] [PMID] [PMCID]
13. Baumann T, Delgado J, Montserrat E. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report. Leukemia 2020;34(7):1954-6. [DOI:10.1038/s41375-020-0870-5] [PMID] [PMCID]
14. Orsini E, Pasquale A, Maggio R, Calabrese E, Mauro FR, Giammartini E, et al. Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19 cells in vivo and in vitro. Br J Haematol 2004;125(6):720-8. [DOI:10.1111/j.1365-2141.2004.04971.x] [PMID]
15. Di Ciaccio P, McCaughan G, Trotman J, Ho PJ, Cheah CY, Gangatharan S, et al. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Intern Med J 2020;50(6):667-79. [DOI:10.1111/imj.14859] [PMID]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.